Browne T R, Dreifuss F E, Dyken P R, Goode D J, Penry J K, Porter R J, White B G, White P T
Neurology. 1975 Jun;25(6):515-24. doi: 10.1212/wnl.25.6.515.
Thirty-seven patients with previously untreated absence seizures were treated with ethosuximide. Seizures were completely controlled in 7 patients (19 percent); 90 to 100 percent control was achieved in 18 patients (49 percent) and 50 to 100 percent control in 35 (95 percent). Plasma ethosuximide concentration increased with dose, but variability in the plasma concentration produced by a given ethosuximide dose made it impossible to predict a patient's plasma concentration from the dose. The therapeutic range of plasma ethosuximide concentration was 40 to 100 mug per milliliter. Patients with evidence of structural central nervous system abnormalities responded as well or better to the drug as patients without such evidence. Ethosuximide did not impair psychometric performance, but rather resulted in improved performance in 17 cases. The side effects of ethosuximide were minor, and rarely required withdrawal of the drug.
37例既往未经治疗的失神发作患者接受了乙琥胺治疗。7例患者（19%）的癫痫发作得到完全控制；18例患者（49%）实现了90%至100%的控制，35例患者（95%）实现了50%至100%的控制。血浆乙琥胺浓度随剂量增加，但给定乙琥胺剂量产生的血浆浓度变异性使得无法根据剂量预测患者的血浆浓度。血浆乙琥胺浓度的治疗范围为每毫升40至100微克。有中枢神经系统结构异常证据的患者对该药物的反应与无此类证据的患者相同或更好。乙琥胺并未损害心理测量表现，反而在17例患者中使表现得到改善。乙琥胺的副作用较小，很少需要停药。
